Related Experiment Video
Updated: Jul 2, 2025
10:01
Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
Published on: October 17, 2018
8.1K
The Chimeric Chaoyang-Zika Vaccine Candidate Is Safe and Protective in Mice
Hao-Long Dong1, Zhi-Li Chen1, Mei-Juan He1
1Academy of Military Medical Sciences, Beijing 100071, China.
Vaccines
|February 24, 2024
Summary
A novel Zika virus (ZIKV) vaccine candidate, ChinZIKV, demonstrated safety and partial protection against lethal ZIKV challenge in mice. Further development for clinical trials is warranted.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Zika virus (ZIKV) is an emerging flavivirus responsible for severe congenital abnormalities.
- No commercial vaccines are currently available for ZIKV prevention.
- A chimeric ZIKV vaccine candidate (ChinZIKV) was previously developed using Chaoyang virus backbone and ZIKV GZ01 prME protein.
Purpose of the Study:
- To evaluate the safety and efficacy of the ChinZIKV vaccine candidate in a mouse model.
- To assess the protective potential of ChinZIKV against a lethal Zika virus challenge.
Main Methods:
- ChinZIKV was administered to adult and suckling immunodeficient mice.
- Mice were challenged with a lethal dose of ZIKV.
- Viral RNA detection in serum and survival rates were monitored.
- Control groups received PBS or ZIKV.
Main Results:
- ChinZIKV was found to be safe in mice, with no detectable viral RNA in serum.
- Mice vaccinated with ChinZIKV survived a lethal ZIKV challenge, unlike unvaccinated controls.
- A single dose of ChinZIKV provided partial protection against ZIKV infection.
Conclusions:
- ChinZIKV is a safe and potentially effective Zika virus vaccine candidate.
- The study supports further investigation of ChinZIKV in human clinical trials.
- This research contributes to the development of ZIKV countermeasures.
